IP Library Granted Patent US 7,138,280
Granted Patent B2
US 7,138,280 · App. 10/263,607 · Granted Nov 21, 2006

Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays

Assignee: Bayer Healthcare AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,138,280
App. No.
10/263,607
Granted
Nov 21, 2006
Kind
B2
Abstract

In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.

Claims (11)

1. A process for the quantitative optical analysis of biological cells labeled with a fluorescent dye, said process comprising the following steps:

a) providing a coherent layer of biological cells labeled with a fluorescent dye applied to a transparent support at the bottom of a reaction vessel and in contact with a solution comprising the fluorescent dye;

b) shining excitation energy through the transparent support to cause the biological cells labeled with the fluorescent dye to exhibit fluorescence;

c) adding a masking dye to the solution comprising the fluorescent dye, the masking dye absorbing at least one of:

i) the excitation energy of the fluorescent dye in the solution; and

ii) the emission light of the fluorescent dye in the solution; and

d) detecting and analyzing the fluorescence of the biological cells labeled with the fluorescent dye through the transparent support;

wherein steps b) and c) are carried out in any order.

2. The process according to claim 1 , wherein the masking dye is water-soluble and has no cytotoxic effects.

3. The process according to claim 1 , wherein the biological cells are labeled with a fluorescent dye which is a FURA-AM dye.

4. The process according to claim 3 , wherein the fluorescent dye is FURA2-AM.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2016
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 039756/0128 →
A CHANGE OF NAME WAS RECORDED ON AUGUST 28, 2009 AT REEL/FRAME 023148/0924. THE ADDRESS SHOULD ALSO HAVE BEEN CHANGE FROM LEVERKUSEN GERMANY 51368 TO BERLIN, GERMANY 13353 Recorded Sep 13, 2010
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 024973/0737 →
CHANGE OF NAME Recorded Aug 28, 2009
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023148/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2005
From: BAYER AKTIENGESELLSCHAFT
To: BAYER HEALTHCARE AG
Reel/Frame 016182/0194 →
Priority Claims (1)
DE 196 21 312 · May 28, 2006 · national
Continuity (3)
Division 0996652200 · Sep 28, 2001
Division 0919409900
Related Publication 20030092081A1 · May 15, 2003